Abstract: Multi-functional antibody polypeptide comprises: (a) a first functional domain, specifically recognizing a cryptic epitope formed by 287th to 302nd amino acid sequence of the EGFR, shown as SEQ ID NO:1, and (b) a second functional domain, specifically recognizing the surface antigen of a human T cell.

Abstract: The present invention provides an anti-human proBDNF monoclonal antibody, and uses thereof in pains. Specifically, the present invention provides uses of antibody polypeptide of tenth to 128th amino acid in a specific recognition pro-BDNF precursor protein structural domain, a nucleic acid sequence for coding the antibody polypeptide, a carrier comprising the nucleic acid sequence, a host comprising the carrier, a pharmaceutical composition comprising the antibody, and the antibody in the preparation of drugs used for alleviating and/or suppressing chronic pains.

Abstract: A nucleic acid for coding a chimeric antigen receptor protein expressed on the surface of a human T lymphocyte. The chimeric antigen receptor protein comprises an extracellular binding domain, a transmembrane domain and an intracellular signal domain that are orderly connected. The extracellular binding domain comprises a single-chain antibody scFv (EGFR) for specific recognition of 287th to 302th amino acid epitopes of a human epidermal growth factor receptor (EGFR).

Abstract: The present invention provides an anti-human proBDNF monoclonal antibody, and uses thereof in pains. Specifically, the present invention provides uses of antibody polypeptide of tenth to 128th amino acid in a specific recognition pro-BDNF precursor protein structural domain, a nucleic acid sequence for coding the antibody polypeptide, a carrier comprising the nucleic acid sequence, a host comprising the carrier, a pharmaceutical composition comprising the antibody, and the antibody in the preparation of drugs used for alleviating and/or suppressing chronic pains.

Abstract: A nucleic acid encoding a chimeric antigen receptor expressed at surface of a T lymphocyte, said chimeric antigen receptor comprises, connected in the order of, an extracellular binding domain, a transmembrane region, and an intracellular signaling domain, wherein the extracellular binding domain comprises a single chain antibody, scFv(GPC3), which specifically recognizes the C-terminal epitope of GPC3. A genetically modified T lymphocyte having a chimeric antigen receptor expressed at surface thereof, and the chimeric antigen receptor is expressed by the nucleic acid described above.

Abstract: Multi-functional antibody polypeptide comprises: (a) a first functional domain, specifically recognizing a cryptic epitope formed by 287th to 302nd amino acid sequence of the EGFR, shown as SEQ ID NO:1, and (b) a second functional domain, specifically recognizing the surface antigen of a human T cell.

Abstract: The present invention provides an epidermal growth factor receptor variant-de4 EGFR protein. The variant lacks the fourth exon of the epidermal growth factor receptor, and promotes tumor cell invasion/metastasis. The present invention also provides an encoding gene for the variant and a method of producing the variant by means of recombination technology.

Abstract: Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion or promoting tumor cell migration.

Abstract: The present invention provides an epidermal growth factor receptor variant-de4 EGFR protein. The variant lacks the fourth exon of the epidermal growth factor receptor, and promotes tumor cell invasion/metastasis. The present invention also provides an encoding gene for the variant and a method of producing the variant by means of recombination technology.

Abstract: The invention provides specific binding proteins and the uses thereof. Particularly, the present invention provides a monoclonal antibody which can effectively bind to epidermal growth factor receptor variant type III (EGFRvIII) or can partially bind to the epidermal growth factor receptor (EGFR) over-expressed in cells, but not bind to EGFR normally-expressed in cells. Furthermore, the present invention said antibody has obvious therapeutic effect on a tumor cell line expressing the EGFRvIII. The invention also provides a method for preparing said monoclonal antibody and a pharmaceutical composition comprising said monoclonal antibody.

Abstract: The invention provides specific binding proteins and the uses thereof. Particularly, the present invention provides a monoclonal antibody which can effectively bind to epidermal growth factor receptor variant type III (EGFRvIII) or can partially bind to the epidermal growth factor receptor (EGFR) over-expressed in cells, but not bind to EGFR normally-expressed in cells. Furthermore, the present invention said antibody has obvious therapeutic effect on a tumor cell line expressing the EGFRvIII. The invention also provides a method for preparing said monoclonal antibody and a pharmaceutical composition comprising said monoclonal antibody.

Abstract: Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion or promoting tumor cell migration.